ANTEROGEN CO., LTD. Logo

ANTEROGEN CO., LTD.

Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.

065660 | KO

Overview

Corporate Details

ISIN(s):
KR7065660003
LEI:
Country:
South Korea
Address:
서울특별시 금천구 디지털로 130, 405호(가산동, 남성플라자), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Anterogen Co., Ltd. is a biotechnology company specializing in the research, development, and commercialization of cell therapy products and orphan drugs. The company's core technology leverages adult stem cells, particularly adipose-derived stem cells (ASCs), to create treatments for various medical conditions. Established with a research institute in 2000, Anterogen was a pioneer in the commercialization of ASC-based therapies in its domestic market. Its product pipeline is developed through clinical trials and focuses on leveraging the immune-modulating effects of its proprietary stem cell technology. The company manages the full lifecycle of its products, from research to manufacturing and distribution.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 813.1 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 798.1 KB
2025-03-21 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 22.9 KB
2025-03-21 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.0 KB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 17.8 KB
2025-03-13 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.0 MB
2025-02-26 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 132.6 KB
2025-02-20 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.3 KB
2025-02-20 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.9 KB
2025-02-10 00:00
Regulatory News Service
[기재정정]주요사항보고서(유상증자결정)
Korean 36.4 KB
2025-01-31 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제3자배정 유상증자)
Korean 5.6 KB
2025-01-31 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험결과) (Wagner grade 1 당뇨병성 족부궤양 환자를 대상으로 한 ALLO-ASC…
Korean 11.4 KB
2025-01-23 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 25.9 KB
2024-12-09 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 762.7 KB

Automate Your Workflow. Get a real-time feed of all ANTEROGEN CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ANTEROGEN CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ANTEROGEN CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.